Shots:
- Part A of P-II (APEX) trial assessed APG777 vs PBO in 123 mod. to sev. AD pts, which met its 1EP with 71% vs 33.8% EASI reduction as well as highest absolute & PBO-adjusted EASI-75 (66.9% vs 24.6%); results were consistent across disease severity, & EASI-75 at Wk. 16 reached 83.3% & 89.5% in 2 highest exposure quartiles
- Trial showed 2EPs consistent with SoC, incl. vIGA 0/1 (34.9% vs 17.3%) & EASI-90 (33.9% vs 14.7%), with highest exposure quartile pts achieving 63.2% for both at Wk. 16, plus itch relief was seen by Wk. 1 (50.7% vs 23.2% per Itch NRS)
- Part A maintenance data (3 & 6mos. dosing) is expected in H1’26, while Part B will enrol ~280 pts randomized to high, medium, or low APG777 dose vs PBO, with readout expected in mid-2026
Ref: Globenewswire | Image: Apogee Therapeutics | Press Release
Related News:- The CVMP Adopts Positive Opinion on Elanco’s Zenrelia for Allergic and Atopic Dermatitis in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
